Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - Zacks Research lifted their Q1 2024 EPS estimates for Kodiak Sciences in a note issued to investors on Wednesday, March 27th. Zacks Research analyst A. Chakraborty now anticipates that the company will post earnings per share of ($1.17) for the quarter, up from their prior forecast of ($1.18). The consensus estimate for Kodiak Sciences' current full-year earnings is ($4.67) per share. Zacks Research also issued estimates for Kodiak Sciences' Q2 2024 earnings at ($1.12) EPS, Q3 2024 earnings at ($1.12) EPS, Q4 2024 earnings at ($1.08) EPS, FY2024 earnings at ($4.50) EPS, Q1 2025 earnings at ($0.94) EPS, Q2 2025 earnings at ($0.81) EPS and FY2025 earnings at ($3.22) EPS.
A number of other analysts have also issued reports on the stock. The Goldman Sachs Group reiterated a "sell" rating and set a $2.00 price objective on shares of Kodiak Sciences in a research note on Monday, December 11th. UBS Group decreased their price target on shares of Kodiak Sciences from $4.00 to $3.00 and set a "neutral" rating for the company in a research report on Thursday, December 21st. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $6.75.
Read Our Latest Stock Analysis on Kodiak Sciences
Kodiak Sciences Stock Down 29.4 %
Shares of KOD traded down $2.19 during mid-day trading on Friday, reaching $5.26. 3,500,034 shares of the stock traded hands, compared to its average volume of 1,015,989. The firm has a market cap of $275.99 million, a price-to-earnings ratio of -1.02 and a beta of 2.17. The stock has a fifty day simple moving average of $5.33 and a 200 day simple moving average of $3.38. Kodiak Sciences has a 12-month low of $1.37 and a 12-month high of $9.80.
Institutional Trading of Kodiak Sciences
Hedge funds have recently bought and sold shares of the company. Point72 Middle East FZE acquired a new position in Kodiak Sciences during the 4th quarter valued at about $27,000. Tower Research Capital LLC TRC increased its stake in Kodiak Sciences by 1,173.9% during the 3rd quarter. Tower Research Capital LLC TRC now owns 16,994 shares of the company's stock valued at $31,000 after buying an additional 15,660 shares during the period. SG Americas Securities LLC acquired a new position in Kodiak Sciences during the 3rd quarter valued at about $37,000. American Century Companies Inc. increased its stake in Kodiak Sciences by 41.1% during the 3rd quarter. American Century Companies Inc. now owns 20,654 shares of the company's stock valued at $37,000 after buying an additional 6,013 shares during the period. Finally, Oxford Asset Management LLP acquired a new position in Kodiak Sciences during the 4th quarter valued at about $41,000. 89.06% of the stock is currently owned by institutional investors.
About Kodiak Sciences
(
Get Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
See Also
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
